Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity
Mayo Clinic
Summary
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Description
PRIMARY OBJECTIVE: I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT. OUTLINE: This is an observational study. Patients undergo blood sample collection and have their medical records reviewed on study.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * 18 years of age or older * Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy * One of the following: * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment * Completed chemotherapy with no cardiotoxicity at least two years post treatment * Patients with cancer who will be initiating syst…
Interventions
- OtherNon-Interventional Study
Non-interventional study
Locations (4)
- Mayo Clinic in ArizonaScottsdale, Arizona
- Mayo Clinic in FloridaJacksonville, Florida
- Moffitt Cancer CenterTampa, Florida
- Mayo Clinic in RochesterRochester, Minnesota